Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

[Prevalence of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].

Han TT, Xu LP, Liu DH, Liu KY, Zhang XH, Chen H, Chen YH, Han W, Wang FR, Wang Y, Wang JZ, Huang XJ.

Zhonghua Xue Ye Xue Za Zhi. 2013 Aug;34(8):651-4. doi: 10.3760/cma.j.issn.0253-2727.2013.08.002. Chinese.

PMID:
23978013
2.

[Clinical risks analysis of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].

Bao X, Zhu Q, Qiu H, Chen F, Xue S, Ma X, Sun A, Wu D.

Zhonghua Xue Ye Xue Za Zhi. 2016 Feb;37(2):138-43. doi: 10.3760/cma.j.issn.0253-2727.2016.02.011. Chinese.

PMID:
27014984
3.

[Monitoring of early Epstein-Barr virus reactivation and preemptive therapy after allogeneic hematopoietic stem cell transplantation].

Lu Y, Wu T, Cao XY, Wang JB, Sun Y, Zhao YL, DA WM, Ji SQ, Tong CR, Lu DP.

Zhonghua Nei Ke Za Zhi. 2011 May;50(5):383-7. Chinese.

PMID:
21624219
4.

Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.

Zallio F, Primon V, Tamiazzo S, Pini M, Baraldi A, Corsetti MT, Gotta F, Bertassello C, Salvi F, Rocchetti A, Levis A.

Clin Transplant. 2013 Jul-Aug;27(4):E491-7. doi: 10.1111/ctr.12172.

PMID:
23781897
5.

Comparison of different rabbit ATG preparation effects on early lymphocyte subset recovery after allogeneic HSCT and its association with EBV-mediated PTLD.

Mensen A, Na IK, Häfer R, Meerbach A, Schlecht M, Pietschmann ML, Gruhn B.

J Cancer Res Clin Oncol. 2014 Nov;140(11):1971-80. doi: 10.1007/s00432-014-1742-z.

PMID:
24962343
6.

Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation.

Peric Z, Cahu X, Chevallier P, Brissot E, Malard F, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Milpied N, Coste-Burel M, Imbert-Marcille BM, Mohty M.

Leukemia. 2011 Jun;25(6):932-8. doi: 10.1038/leu.2011.26.

PMID:
21350556
7.

Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.

Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, Theunissen K, Kalwak K, Hubacek P, Sica S, Nozzoli C, Fagioli F, Matthes S, Diaz MA, Migliavacca M, Balduzzi A, Tomaszewska A, Camara Rde L, van Biezen A, Hoek J, Iacobelli S, Einsele H, Cesaro S; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation..

Clin Infect Dis. 2013 Sep;57(6):794-802. doi: 10.1093/cid/cit391.

8.

Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation.

Xuan L, Jiang X, Sun J, Zhang Y, Huang F, Fan Z, Guo X, Dai M, Liu C, Yu G, Zhang X, Wu M, Huang X, Liu Q.

Transplantation. 2013 Sep;96(6):560-6. doi: 10.1097/TP.0b013e31829d38af.

PMID:
23842192
9.

Features of Epstein-Barr virus reactivation after allogeneic hematopoietic cell transplantation in Korean children living in an area of high seroprevalence against Epstein-Barr virus.

Han SB, Bae EY, Lee JW, Jang PS, Lee DG, Chung NG, Jeong DC, Cho B, Lee SJ, Kang JH, Kim HK.

Int J Hematol. 2014 Aug;100(2):188-99. doi: 10.1007/s12185-014-1613-z.

PMID:
24981711
10.

Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Société Française de Greffe de Moelle-Therapie Cellulaire collaborative study.

Dumas PY, Ruggeri A, Robin M, Crotta A, Abraham J, Forcade E, Bay JO, Michallet M, Bertrand Y, Socié G, Ionescu I, Gluckman E, Milpied N, Rocha V.

Bone Marrow Transplant. 2013 Feb;48(2):253-6. doi: 10.1038/bmt.2012.117.

PMID:
22773124
11.

[Clinical outcomes of allogeneic hematopoietic stem cell transplantation patients with co-activation of cytomegalovirus and Epstein-Barr virus].

Song T, Chen G, Zhang X, Xu Y, Chen J, Wang Y, Ye L, Xu J, Wu D, Miao J.

Zhonghua Yi Xue Za Zhi. 2014 Nov 4;94(40):3135-9. Chinese.

PMID:
25573307
12.

Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies.

Xuan L, Huang F, Fan Z, Zhou H, Zhang X, Yu G, Zhang Y, Liu C, Sun J, Liu Q.

J Hematol Oncol. 2012 Aug 2;5:46. doi: 10.1186/1756-8722-5-46.

13.

Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.

van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW, Verdonck LF, Löwenberg B, Cornelissen JJ.

Blood. 2002 Jun 15;99(12):4364-9.

14.

The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention?

Greenfield HM, Gharib MI, Turner AJ, Guiver M, Carr T, Will AM, Wynn RF.

Pediatr Blood Cancer. 2006 Aug;47(2):200-5.

PMID:
16206207
15.

Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease.

Gärtner BC, Schäfer H, Marggraff K, Eisele G, Schäfer M, Dilloo D, Roemer K, Laws HJ, Sester M, Sester U, Einsele H, Mueller-Lantzsch N.

J Clin Microbiol. 2002 Feb;40(2):351-8. Erratum in: J Clin Microbiol 2002 Jun;40(6):2316.

16.
17.

Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation.

Carpenter B, Haque T, Dimopoulou M, Atkinson C, Roughton M, Grace S, Denovan S, Fielding A, Kottaridis PD, Griffiths P, Mackinnon S, Emery V, Chakraverty R.

Transplantation. 2010 Sep 15;90(5):564-70. doi: 10.1097/TP.0b013e3181e7a3bf.

PMID:
20555307
18.

Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.

Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T, Gualandi F, Bregante S, Ibatici A, di Grazia C, Dominietto A, Varaldo R, Bruno B, Frassoni F, Van Lint MT, Bacigalupo A.

Biol Blood Marrow Transplant. 2011 Jun;17(6):901-7. doi: 10.1016/j.bbmt.2010.10.003.

19.

Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation.

Chen DB, Song QJ, Chen YX, Chen YH, Shen DH.

Int J Hematol. 2013 Jan;97(1):117-24. doi: 10.1007/s12185-012-1244-1.

PMID:
23255160
20.

Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients.

Barker JN, Martin PL, Coad JE, DeFor T, Trigg ME, Kurtzberg J, Weisdorf DJ, Wagner J.

Biol Blood Marrow Transplant. 2001;7(7):395-9.

PMID:
11529490
Items per page

Supplemental Content

Support Center